Ligand Pharmaceuticals Incorporated (LGND) Earnings History
Annual and quarterly earnings data from 1994 to 2024
Loading earnings history...
LGND EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LGND Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 93.4% | -13.5% | -2.4% |
| 2023 | 73.3% | 9.1% | 39.7% |
| 2022 | 73.1% | 1.5% | -17.0% |
| 2021 | 74.3% | 43.0% | 23.7% |
| 2020 | 81.4% | 22.9% | -1.8% |
Download Data
Export LGND earnings history in CSV or JSON format
Free sign-in required to download data
Ligand Pharmaceuticals Incorporated (LGND) Earnings Overview
As of May 7, 2026, Ligand Pharmaceuticals Incorporated (LGND) reported trailing twelve-month net income of $49M, reflecting -107.5% year-over-year growth. The company earned $2.41 per diluted share over the past four quarters, with a net profit margin of -2.4%.
Looking at the long-term picture, LGND's historical earnings data spans multiple years. The company achieved its highest annual net income of $629M in fiscal 2019.
Ligand Pharmaceuticals Incorporated maintains positive profitability with a gross margin of 93.4%, operating margin of -13.5%, and net margin of -2.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), INVA ($504M net income, 63.8% margin), OMAB ($5.34B net income, 33.5% margin), LGND has outperformed on profitability metrics. Compare LGND vs PRGO →
LGND Earnings vs Peers
Earnings metrics vs comparable public companies
LGND Historical Earnings Data (1994–2024)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$4M | -107.7% | -$23M | $-0.22 | -2.4% | -13.5% |
| 2023 | $52M | +256.3% | $12M | $2.94 | 39.7% | 9.1% |
| 2022 | -$33M | -158.4% | $3M | $-1.98 | -17.0% | 1.5% |
| 2021 | $57M | +2014.2% | $104M | $3.34 | 23.7% | 43.0% |
| 2020 | -$3M | -100.5% | $38M | $-0.18 | -1.8% | 22.9% |
| 2019 | $629M | +339.1% | $807M | $31.85 | 523.2% | 671.0% |
| 2018 | $143M | +1041.5% | $164M | $5.96 | 57.0% | 65.1% |
| 2017 | $13M | +867.5% | $68M | $0.53 | 8.9% | 48.2% |
| 2016 | -$2M | -100.6% | $44M | $-0.08 | -1.5% | 40.3% |
| 2015 | $257M | +2039.9% | $27M | $12.12 | 357.8% | 38.0% |
See LGND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LGND Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LGND vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLGND — Frequently Asked Questions
Quick answers to the most common questions about buying LGND stock.
Is LGND growing earnings?
LGND EPS fell to $2.41, with earnings declining -107.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $49M.
What are LGND's profit margins?
Ligand Pharmaceuticals Incorporated net margin is -2.4%, with operating margin at -13.5%. Below-average margins reflect competitive or cost pressures.
How consistent are LGND's earnings?
LGND earnings data spans 1994-2024. The declining earnings trend is -107.5% YoY. Historical data enables comparison across business cycles.